CONFERENCE COVERAGE
15th ICML ADC Presentation Overview
The International Conference on Malignant Lymphoma (ICML), which will be held June 18-22, 2019 in the Palazzo dei Congressi, Lugano, Switzerland and is organized by the Institute of Oncology Research (IOR) in cooperation with the American Association for Cancer Research (AACR), is one of the must-attend events for the scientific community involved in the study and treatment of lymphoid...
ADC Therapeutics Expands Agreement with Synaffix
The Netherlands-based biotechnology company Synaffix, which develops clinical-stage technologies for the development of best-in-class antibody-drug conjugates or ADCs, confirmed that ADC Therapeutics has triggered a third target-specific license under its existing Commercial License Agreement...
The Evolving Market for Antibody-drug Conjugates
The scale of patient demand has fueled an overarching healthcare market need to expand the drug development pipeline to generate more biologics to treat multiple diseases and innovative new biopharmaceuticals to further enhance the...
Understanding of the Underlying Mechanisms of Target-Independent Uptake and Toxicity
With 4 approved agents, antibody-drug conjugates or ADC have shown to be a very promising class of therapeutics. While the concept of ADCs is not...
Characterization of Antibody-drug Conjugates
Antibody-drug conjugates (ADCs) represent a rapidly growing class of anti-cancer therapeutics in which a potent small molecule is linked to a monoclonal antibody. To-date, two antibody-drug conjugates have been approved by regulators in the United...
